Vincerx Pharma Inc (VINC) AI Stock Analysis

• Market Cap: $1.83M
• Dividend Yield: N/A
• Average Volume (3M): 957.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: N/A
• EPS Growth: 55.21%
• Country: US
• Employees: 42
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -20.62
• Shares Outstanding: 2,239,580
• 10 Day Avg. Volume: 621,090
• 30 Day Avg. Volume: 957,256
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 3.06
• Price to Cash Flow (P/CF): -0.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.00
• Price Target Upside: 143.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

Vincerx Pharma Inc's overall stock score is significantly impacted by its weak financial performance, characterized by high debt, negative margins, and poor cash flow. Technical analysis suggests a bearish trend with a lack of positive momentum. Valuation metrics highlight challenges, with a negative P/E ratio and no dividend yield. The absence of substantial updates from the earnings call keeps this component neutral. Overall, the company's financial challenges are the predominant factor affecting its stock score.

Positive Factors

Safety and Tolerability

VIP943 has shown favorable safety and tolerability, with no dose-limiting toxicities reported in the 22 patients treated.

Negative Factors

Financial Resources

VINC ended with $10.1M in cash and equivalents, indicating limited financial resources.

Partnership Dependency

The company continues to look for a partner to advance development of enitociclib and VIP236, suggesting dependency on external collaboration for progress.

Vincerx Pharma Inc Business Overview & Revenue Model

Company Description

Vincerx Pharma Inc (VINC) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address unmet medical needs in oncology. The company aims to advance its pipeline of targeted therapies and precision oncology medicines to improve outcomes for cancer patients. Vincerx Pharma operates within the pharmaceutical sector, primarily focusing on the development and commercialization of small molecule drugs and biologics for cancer treatment.

How the Company Makes Money

Vincerx Pharma makes money through the development, commercialization, and potential future sale of its proprietary drug candidates. The company derives revenue primarily from partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships often provide upfront payments, milestone payments, and potential royalties on sales of successfully commercialized products. Additionally, Vincerx may engage in research and development collaborations to share the costs and risks associated with drug development, while benefiting from the resources and expertise of its partners. As a clinical-stage company, significant revenue generation is contingent upon the successful development and approval of its drug candidates.

Vincerx Pharma Inc Financial Statement Overview

Summary

Vincerx Pharma Inc is facing substantial financial challenges across its income statement, balance sheet, and cash flow. The company is in a highly unprofitable position with negative margins, high leverage, and negative cash flow, suggesting a precarious financial trajectory. While there is some evidence of revenue generation, the overall financial health remains weak, requiring significant strategic adjustments to improve sustainability.

Income Statement

Vincerx Pharma Inc has shown some revenue generation in the TTM, but overall financial performance remains challenging with substantial losses. The company has a negative net profit margin and EBIT margin, indicating persistent unprofitability. Although there is a slight revenue growth from zero, the magnitude of losses continues to weigh heavily on the income statement.

Balance Sheet

The balance sheet presents a weak financial position with a high debt-to-equity ratio due to limited equity and increasing liabilities. The equity ratio has decreased over time, highlighting reduced stability. However, there is still some stockholder equity, which provides a cushion against liabilities, albeit a diminishing one.

Cash Flow

Cash flow analysis reveals significant challenges, with substantial negative operating cash flow and free cash flow. Despite some financing cash inflow, the company struggles to convert this into positive cash flow from operations. This indicates an inability to internally generate sufficient cash to cover operating expenses.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.31M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
522.00K	-915.00K	-939.00K	-340.00K	-173.00K	-173.00K
	EBIT
-28.17M	-42.61M	-73.57M	-62.66M	-10.71M	-45.00K
	EBITDA
-27.10M	-42.61M	-68.67M	-62.66M	-10.71M	9.00K
	Net Income Common Stockholders
-27.03M	-40.16M	-57.16M	-15.61M	-10.73M	-45.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
0.00	12.78M	52.46M	111.46M	61.79M	684.71K
	Total Assets
0.00	18.22M	59.29M	117.68M	63.19M	1.00K
	Total Debt
0.00	2.50M	3.44M	4.17M	0.00	0.00
	Net Debt
0.00	-10.28M	-8.23M	-107.28M	-61.79M	-684.71K
	Total Liabilities
44.00K	7.00M	11.62M	17.36M	5.50M	44.00K
	Stockholders Equity
-44.00K	11.22M	47.67M	100.32M	57.69M	-44.00K
Cash Flow		Free Cash Flow
-27.96M	-40.45M	-59.60M	-38.66M	-2.28M	―
	Operating Cash Flow
-27.96M	-40.45M	-59.60M	-33.40M	-2.28M	―
	Investing Cash Flow
-1.21M	41.50M	-40.58M	-5.26M	-65.64M	-65.64M
	Financing Cash Flow
17.02M	114.00K	280.00K	88.45M	64.07M	66.46M

Vincerx Pharma Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VINC, the sentiment is Negative. The current price of 0.82 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 2.18, and below the 200-day MA of 8.69, indicating a bearish trend. The MACD of -0.35 indicates Negative momentum. The RSI at 29.24 is Positive, neither overbought nor oversold. The STOCH value of 11.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VINC.

Vincerx Pharma Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%
CYCN	45 Neutral	$6.95M	―	-30.36%	―	―	86.52%
KPTI	41 Neutral	$62.62M	―	41.08%	―	-0.55%	49.85%
IMUX	34 Underperform	$99.09M	―	-216.24%	―	―	61.97%
BTAI	33 Underperform	$8.13M	―	82.91%	―	83.25%	70.75%
VINC	30 Underperform	$1.83M	―	-217.55%	―	―	55.21%

Vincerx Pharma Inc Corporate Events

Vincerx Pharma Inc. Announces Merger with Oqory

Vincerx Pharma Inc. has announced a potential merger with Oqory, Inc., as outlined in a binding term sheet, where Oqory stockholders would receive shares of Vincerx common stock. Following the merger, Oqory’s equity holders are expected to own approximately 95% of the combined company. The merger includes conditions such as securing interim financing and stockholder approval, and poses significant implications for Vincerx’s market positioning, as the company will see a substantial change in its ownership structure.

Vincerx Pharma Announces Merger, Leadership Changes, and Financing

Vincerx Pharma has entered into a binding term sheet for a proposed merger with Oqory, Inc., a clinical-stage company developing ADCs. Upon completion, Oqory shareholders will own 95% of the combined entity. This merger aims to enhance Vincerx’s pipeline with Oqory’s differentiated Phase 3 TROP2 ADC, showing favorable clinical results. Concurrently, Vincerx is implementing cost-control measures, including leadership changes, to facilitate the merger process. The company plans a $20 million equity offering and has secured $1.5 million in interim financing to support these strategic moves.